BioHarvest Grants 516,812 Options and 264,121 RSUs Under Long-Term Incentive Plan
BioHarvest Sciences’ board approved 516,812 stock options and 264,121 RSUs under its equity incentive plan to align employees, officers and directors with shareholder interests. All options and RSUs are priced at March 13 closing value, vest quarterly over three years and, for options, carry a ten-year term.
1. Grant Details
BioHarvest Sciences’ board has approved long-term incentive awards totaling 516,812 stock options and 264,121 restricted share units for employees, officers and directors under the company’s equity incentive plan. This award package is designed to directly tie compensation to shareholder value creation by issuing equity rather than cash payouts.
2. Award Terms and Vesting
All stock options and RSUs are priced at the closing share value on March 13, 2026. The RSUs and options vest quarterly over a three-year period beginning March 13, 2026, and the options carry a ten-year exercise window.
3. Strategic Impact
By using equity-based awards, BioHarvest aims to retain top scientific and operational talent while preserving cash resources. The grants reinforce alignment between the team’s performance and long-term growth of the patented Botanical Synthesis platform across nutraceutical and CDMO segments.